Ipswich Investment Management Co. Inc. maintained its position in Eli Lilly and Company (NYSE:LLY) during the second quarter, Holdings Channel reports. The institutional investor owned 8,280 shares of the company’s stock at the end of the second quarter. Ipswich Investment Management Co. Inc.’s holdings in Eli Lilly and were worth $681,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Ronna Sue Cohen increased its stake in Eli Lilly and by 0.4% in the second quarter. Ronna Sue Cohen now owns 2,466 shares of the company’s stock valued at $203,000 after buying an additional 9 shares during the period. Sunbelt Securities Inc. increased its stake in Eli Lilly and by 0.5% in the first quarter. Sunbelt Securities Inc. now owns 3,721 shares of the company’s stock valued at $313,000 after buying an additional 17 shares during the last quarter. Northwest Quadrant Wealth Management LLC increased its stake in Eli Lilly and by 0.5% in the first quarter. Northwest Quadrant Wealth Management LLC now owns 3,589 shares of the company’s stock valued at $290,000 after buying an additional 19 shares during the last quarter. Pillar Pacific Capital Management LLC increased its stake in Eli Lilly and by 0.3% in the first quarter. Pillar Pacific Capital Management LLC now owns 7,077 shares of the company’s stock valued at $595,000 after buying an additional 20 shares during the last quarter. Finally, Guardian Life Insurance Co. of America increased its stake in Eli Lilly and by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 3,747 shares of the company’s stock valued at $315,000 after buying an additional 25 shares during the last quarter. 75.61% of the stock is owned by institutional investors.

Shares of Eli Lilly and Company (NYSE LLY) traded down 0.18% during midday trading on Friday, reaching $81.38. The company had a trading volume of 1,238,980 shares. The company’s 50 day moving average price is $83.00 and its 200 day moving average price is $81.69. Eli Lilly and Company has a 52-week low of $64.18 and a 52-week high of $86.72. The stock has a market capitalization of $85.86 billion, a PE ratio of 35.21 and a beta of 0.34.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.05 by $0.06. The firm had revenue of $5.82 billion for the quarter, compared to the consensus estimate of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The company’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.86 earnings per share. Equities research analysts expect that Eli Lilly and Company will post $4.16 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Tuesday, August 15th will be issued a $0.52 dividend. The ex-dividend date is Friday, August 11th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.54%. Eli Lilly and’s dividend payout ratio (DPR) is 90.04%.

TRADEMARK VIOLATION NOTICE: This piece was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.dailypolitical.com/2017/08/11/ipswich-investment-management-co-inc-has-681000-stake-in-eli-lilly-and-company-nyselly.html.

Several analysts recently weighed in on the company. Berenberg Bank restated a “buy” rating and issued a $98.00 price objective on shares of Eli Lilly and in a report on Friday, August 4th. BMO Capital Markets restated a “sell” rating and issued a $73.00 price objective on shares of Eli Lilly and in a report on Friday, August 4th. TheStreet upgraded Eli Lilly and from a “c+” rating to a “b+” rating in a report on Tuesday, July 25th. UBS AG downgraded Eli Lilly and to a “hold” rating and set a $85.00 price objective for the company. in a report on Wednesday, July 26th. Finally, Leerink Swann downgraded Eli Lilly and from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $93.00 to $90.00 in a report on Wednesday, July 26th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $88.27.

In other news, major shareholder Lilly Endowment Inc sold 220,000 shares of the business’s stock in a transaction on Monday, July 31st. The stock was sold at an average price of $83.09, for a total value of $18,279,800.00. Following the completion of the transaction, the insider now directly owns 124,049,283 shares of the company’s stock, valued at $10,307,254,924.47. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Michael J. Harrington sold 22,833 shares of the business’s stock in a transaction on Friday, June 9th. The stock was sold at an average price of $79.97, for a total value of $1,825,955.01. Following the completion of the transaction, the vice president now directly owns 62,056 shares of the company’s stock, valued at $4,962,618.32. The disclosure for this sale can be found here. Over the last three months, insiders sold 669,733 shares of company stock valued at $55,845,287. Insiders own 0.20% of the company’s stock.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.